Natera is a global leader in cell-free DNA (cfDNA) testing, focused on developing genetic diagnostics across oncology, women's health, and organ health. The company's technical work spans molecular biology, bioinformatics, and AI. Its operations are supported by laboratories that are CAP-accredited, CLIA-certified, and ISO 13485-certified, with offices in San Carlos, California, and Austin, Texas, in addition to a worldwide presence.
The company's product portfolio includes several distinct diagnostic tests. Panorama™ is a non-invasive prenatal screening test. Signatera™ is a personalized test designed for molecular residual disease detection and cancer recurrence monitoring. Prospera™ is used for the assessment of organ transplant rejection. These products are part of Natera's mission to integrate personalized genetic testing into standard clinical care.
Natera's scientific work has resulted in a body of over 300 peer-reviewed publications, supporting the clinical validity of its assays. The firm operates at the intersection of genetic diagnostics, advanced bioinformatics, and clinical research.
